Modified drug combination may reduce risk of recurrence for some breast cancer patients

Oncologists at VCU Massey Cancer Center were invited to co-author an editorial published in the Journal of Clinical Oncology providing expert commentary on findings from a large study conducted by German investigators that a modified drug combination may lead to a decreased chance of disease recurrence for women with high Continue Reading

Novel paradigm in drug development

Traditional medicines mostly function as inhibitors, attacking the disease-relevant proteins that cause cancer, by binding to their accessible pockets. Following this strategy, only ~20% of all proteins are chemically addressable, leaving some of the most relevant targets inaccessible to therapeutic development. Targeted protein degradation (TPD) is a novel approach in Continue Reading

Alzheimer’s drug reverses brain damage from adolescent alcohol exposure in rats

A drug used to slow cognitive decline in adults with Alzheimer’s disease appears to reverse brain inflammation and neuron damage in rats exposed to alcohol during adolescence. In a study described in the journal Scientific Reports, Duke Health researchers sought to understand how intermittent binge drinking changes the hippocampus—a region Continue Reading

Novel combination of drugs may overcome drug-resistant cancer cells

Cancer cells can adapt and develop resistance to chemotherapy drugs, making it difficult to eradicate tumors. A new study led by investigators from Brigham and Women’s Hospital suggests that a combination of three drugs, including a new class of glucose-6-phosphate dehydrogenase inhibitors, could overcome cross-therapy resistance. The results of the Continue Reading

FDA approves drug for most deadly form of tuberculosis

(HealthDay)—A new drug has been approved as part of a powerful, three-pronged treatment regimen for the most deadly strain of tuberculosis, the U.S. Food and Drug Administration announced Wednesday. Pretomanid tablets were approved to be used with bedaquiline and linezolid in adults with extensive multidrug-resistant tuberculosis (XDR-TB) of the lungs. Continue Reading

Charcoal-based drug delivery system improves efficacy of common herpes drug

A study led by researchers from the University of Illinois at Chicago has found that combining acyclovir—a commonly prescribed topical herpes medication—with particles of activated carbon improves efficacy of the drug. This new approach allows for less frequent dosing and overall course of treatment while providing some protection from infection Continue Reading